Patents Assigned to XSPRAY PHARMA AB
  • Pharmaceutical compositions
    Patent number: 12576071
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: December 2, 2024
    Date of Patent: March 17, 2026
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB
    Publication number: 20250375449
    Abstract: Disclosed herein is a composition comprising: an amorphous solid dispersion (ASD) comprising nilotinib and at least one polymeric stabilizing and matrix-forming component; and at least one solid organic acid in admixture with the ASD, and uses thereof in the treatment of proliferative disorder.
    Type: Application
    Filed: August 25, 2025
    Publication date: December 11, 2025
    Applicant: XSPRAY PHARMA AB
    Inventors: Andreas FISCHER, Thomas ANDERSSON
  • Pharmaceutical compositions comprising nilotinib
    Patent number: 12419892
    Abstract: Disclosed herein is a composition comprising: an amorphous solid dispersion (ASD) comprising nilotinib and at least one polymeric stabilizing and matrix-forming component; and at least one solid organic acid in admixture with the ASD, and uses thereof in the treatment of proliferative disorder.
    Type: Grant
    Filed: November 8, 2024
    Date of Patent: September 23, 2025
    Assignee: XSPRAY PHARMA AB
    Inventors: Andreas Fischer, Thomas Andersson
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20250090511
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Application
    Filed: December 2, 2024
    Publication date: March 20, 2025
    Applicant: XSPRAY PHARMA AB
    Inventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20240398769
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Application
    Filed: August 15, 2024
    Publication date: December 5, 2024
    Applicant: XSPRAY PHARMA AB
    Inventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
  • Pharmaceutical compositions
    Patent number: 12144804
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: July 22, 2024
    Date of Patent: November 19, 2024
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20240374577
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Application
    Filed: July 22, 2024
    Publication date: November 14, 2024
    Applicant: XSPRAY PHARMA AB
    Inventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
  • Pharmaceutical compositions
    Patent number: 12076314
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: January 12, 2024
    Date of Patent: September 3, 2024
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20240189290
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Application
    Filed: January 12, 2024
    Publication date: June 13, 2024
    Applicant: XSPRAY PHARMA AB
    Inventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
  • Pharmaceutical compositions
    Patent number: 11963951
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: April 23, 2024
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • FAST DISSOLVING PHARMACEUTICAL COMPOSITIONS
    Publication number: 20240024248
    Abstract: The present disclosure relates to the field of pharmaceutical compositions. Furthermore, the present invention relates to an immediate release pharmaceutical composition in the form of a non-effervescent tablet composition comprising dasatinib and a gas generating agent.
    Type: Application
    Filed: July 27, 2023
    Publication date: January 25, 2024
    Applicant: XSPRAY PHARMA AB
    Inventors: Magnus BRISANDER, Thomas MEIJER, Victor SÖDERBERG
  • Rapidly disintegrating solid oral dosage forms containing dasatinib
    Patent number: 11833249
    Abstract: The instant application relates to the field of pharmaceutical compositions comprising dasatinb. Furthermore, the instant application relates to a method of treating proliferative disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said compositions.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: December 5, 2023
    Assignee: XSPRAY PHARMA AB
    Inventors: Per Andersson, Thomas Meijer, Victor Söderberg
  • FAST DISSOLVING PHARMACEUTICAL COMPOSITIONS
    Publication number: 20230121325
    Abstract: The present disclosure relates to the field of pharmaceutical compositions. Furthermore, the present invention relates to an immediate release pharmaceutical composition in the form of a non-effervescent tablet composition comprising dasatinib and a gas generating agent.
    Type: Application
    Filed: December 12, 2022
    Publication date: April 20, 2023
    Applicant: XSPRAY PHARMA AB
    Inventors: Magnus BRISANDER, Thomas MEIJER, Victor SÖDERBERG
  • Fast dissolving pharmaceutical compositions
    Patent number: 11529351
    Abstract: The present disclosure relates to the field of pharmaceutical compositions. Furthermore, the present invention relates to an immediate release pharmaceutical composition in the form of a non-effervescent tablet composition comprising dasatinib and a gas generating agent.
    Type: Grant
    Filed: January 21, 2022
    Date of Patent: December 20, 2022
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Thomas Meijer, Victor Söderberg
  • Pharmaceutical compositions
    Patent number: 11517562
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: June 1, 2022
    Date of Patent: December 6, 2022
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20220296575
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Application
    Filed: June 1, 2022
    Publication date: September 22, 2022
    Applicant: XSPRAY PHARMA AB
    Inventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
  • Pharmaceutical compositions
    Patent number: 11426391
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: August 30, 2022
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORMS CONTAINING DASATINIB
    Publication number: 20220257519
    Abstract: The instant application relates to the field of pharmaceutical compositions comprising dasatinb. Furthermore, the instant application relates to a method of treating proliferative disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said compositions.
    Type: Application
    Filed: May 6, 2022
    Publication date: August 18, 2022
    Applicant: XSPRAY PHARMA AB
    Inventors: Per ANDERSSON, Thomas MEIJER, Victor SÖDERBERG
  • FAST DISSOLVING PHARMACEUTICAL COMPOSITIONS
    Publication number: 20220233532
    Abstract: The present disclosure relates to the field of pharmaceutical compositions. Furthermore, the present invention relates to an immediate release pharmaceutical composition in the form of a non-effervescent tablet composition comprising dasatinib and a gas generating agent.
    Type: Application
    Filed: January 21, 2022
    Publication date: July 28, 2022
    Applicant: XSPRAY PHARMA AB
    Inventors: Magnus BRISANDER, Thomas MEIJER, Victor SÖDERBERG
  • Pharmaceutical compositions
    Patent number: 11376243
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: July 5, 2022
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand